Geometrically complex intravaginal rings, systems and methods of making the same

US11219595B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11219595-B2
Application numberUS-201816139481-A
CountryUS
Kind codeB2
Filing dateSep 24, 2018
Priority dateMar 23, 2016
Publication dateJan 11, 2022
Grant dateJan 11, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Geometrically complex intravaginal rings, systems and methods of making the same are provided herein. Disclosed herein are geometrically complex intravaginal rings with tunable and enhanced drug release, which in some embodiments can be fabricated by 3D printing technologies. The disclosed IVRs include a ring structure comprising a plurality of unit cells or macroscopic and/or microscopic architecture, which can be tuned to control the loading capacity of an active compound within the IVR, the diffusion of an active compound from the IVR, the surface area of the IVR, and/or the mechanical properties of the IVR. The disclosed geometrically complex IVRs can provide superior control over drug loading and drug release compared to conventional IVRs fabricated by injection molding or hot-melt extrusion.

First claim

Opening claim text (preview).

What is claimed is: 1. A geometrically complex intravaginal ring (IVR), the IVR comprising: a three dimensional ring structure comprising a body forming an inner diameter and an outer diameter; a plurality of unit cells, each of the unit cells comprising a macroscopic and/or microscopic architecture, wherein each of the unit cells forms a geometric shape, wherein the plurality of unit cells together form the body of the ring structure, wherein the IVR comprises one or more types of unit cells, wherein each type of unit cell varies in size, shape, configuration, surface area and/or three dimensional geometry; a void volume that is regularly or irregularly distributed continuously or in discrete volumes amongst the plurality of unit cells, wherein the void volume is greater than or equal to about 10; and an active compound; wherein the macroscopic architecture and/or microscopic architecture of the unit cells is configured to control a loading capacity of the active compound within or on the IVR, a diffusion rate of the active compound from the IVR, a surface area of the IVR, a fractional volume of the IVR, and/or a mechanical property of the IVR. 2. The geometrically complex IVR of claim 1 , wherein a fractional volume of the IVR is about 0.1 to about 0.9, wherein the fractional volume is calculated based on Equation 2: Volume Fraction×Loading   Equation 2 wherein the Volume Fraction is calculated based on Equation 1: Geometric ⁢ ⁢ Complexity ⁢ ⁢ by ⁢ ⁢ Volume ⁢ ⁢ Fraction ⁢ ⁢ : ⁢ ⁢ Volume ⁢ ⁢ of ⁢ ⁢ IVR ⁢ ⁢ with ⁢ ⁢ Void ⁢ ⁢ Spaces Volume ⁢ ⁢ of ⁢ ⁢ Solid ⁢ ⁢ IVR < 1. Equation ⁢ ⁢ 1 3. The geometrically complex IVR of claim 1 , wherein the outer diameter, inner diameter, and/or a cross-section of the IVR can vary throughout the three dimensional ring structure. 4. The geometrically complex IVR of claim 1 , wherein a shape, size, and/or surface area of the IVR is fabricated by 3D printing; and wherein the active compound is incorporated into the IVR during or after 3D printing. 5. The geometrically complex IVR of claim 4 , wherein the 3D printing used in fabrication comprises continuous liquid interface production (CLIP). 6. The geometrically complex IVR of claim 4 , wherein the active compound is incorporated into the IVR after 3D printing by coating, absorption, infusion, or adsorption of active compound onto the IVR. 7. The geometrically complex IVR of claim 4 , further comprising providing a gel-like compound, wherein the gel-like compound is incorporated into the IVR after 3D printing by filling a void volume of the IVR. 8. The geometrically complex IVR of claim 1 , wherein the active compound is captured inside one or more nanoparticles incorporated into the IVR. 9. The geometrically complex IVR of claim 1 , wherein a shape, size, and/or surface area of the IVR is produced by a foaming method or by a die-cut method. 10. The geometrically complex IVR of any of claim 1 , wherein the IVR is configured to control the rate and/or duration of diffusion of the active compound from the IVR, wherein the active compound is released from the IVR for an extended period of time, optionally 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50 days or more. 11. The geometrically complex IVR of claim 1 , wherein the active compound comprises a therapeutic compound selected from an antiviral, antiretroviral, microbicide, contraceptive, antibiotic, hormone, pre-exposure prophylaxis, small molecule drug, macromolecule drug, biopharmaceutical, biologics, chemotherapeutic, other pharmaceutical compound, and combinations thereof. 12. The geometrically complex IVR of claim 1 , further comprising an additive selected from the group consisting of a pore-forming agent, a plasticizer, a stabilizer, a filler and combinations thereof, wherein the pore-forming agent comprises one or more of PEG 3000, PEG 6000, PEG 8000, hydroxypropyl cellulose, PVP 10000 , and PVA 10000 , wherein the pore-forming agent is configured to create aqueous diffusion pathways for a drug molecule over time. 13. The geometrically complex IVR of claim 1 , wherein the plurality of unit cells comprise a resin formulation, wherein the resin formulation comprises additives configured to influence drug solubility, viscosity, porosity, stability, or mechanical properties of the IVR during processing, or configured to influence surface properties, swelling, stability, or mechanical properties during packaging, storage, or use. 14. The geometrically complex IVR of claim 1 , wherein the IVR is configured to release two or more active compounds simultaneously or iteratively and a

Assignees

Inventors

Classifications

  • Materials specially adapted for additive manufacturing · CPC title

  • Devices for introducing or retaining media, e.g. remedies, in cavities of the body (A61M25/00 takes precedence {; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008}) · CPC title

  • using layers of liquid which are selectively solidified · CPC title

  • having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title

  • hydrophobic · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11219595B2 cover?
Geometrically complex intravaginal rings, systems and methods of making the same are provided herein. Disclosed herein are geometrically complex intravaginal rings with tunable and enhanced drug release, which in some embodiments can be fabricated by 3D printing technologies. The disclosed IVRs include a ring structure comprising a plurality of unit cells or macroscopic and/or microscopic archi…
Who is the assignee on this patent?
Univ North Carolina Chapel Hill
What technology area does this patent fall under?
Primary CPC classification A61K9/0036. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).